Apart from the already existing players such as Pfizer, Sanofi, Taiho Pharma, Ono Pharma, along with many others, there are several emerging key players which are expected to change the Metastatic Colorectal Cancer treatment scenario in the coming years owing to the positive outcomes of the emerging pipeline candidates in their developmental stage, which includes Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, Merck, AB Science, Pfizer, Daiichi Sankyo/Astrazeneca, Merck/Eisai, Mirati Therapeutics, Merck, Cardiff Oncologyalong and several others.
“Metastatic Colorectal Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Metastatic Colorectal Cancer Market.
The Metastatic Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Metastatic Colorectal Cancer and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Metastatic Colorectal Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Route of Administration
Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as –
Products have been categorized under various Molecule types, such as –
Metastatic Colorectal Cancer Emerging Therapies Mechanism of Action (MOA) Types:
ATP binding cassette transporter subfamily G member 2 inhibitors
KRAS protein inhibitors
Epidermal growth factor receptor antagonists
Polo-like kinase 1 inhibitor
Cyclin-dependent kinase 4 inhibitors
Interleukin-15 receptor agonists
Immunologic cytotoxicity; T lymphocyte replacements
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Recent Clinical, Commercial and Regulatory Developments in the Metastatic Colorectal Cancer Market
On 11 May 2021, Shanghai Henlius Biotech and NeuPharma entered into a drug technology license agreement. NeuPharma will grant the Company a sublicensable exclusive license for related licensed patents and licensed know-how necessary or reasonably useful for the Company to research, develop, produce and commercialize the Licensed Product within the Licensed Territory (China).
In November 2021, the US FDA granted a fast-track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer (mCRC). This serves as a strong external validation of arfolitixorin’s potential to benefit patients with this devastating disease.
In January 2022, Gritstone bio, Inc. announced that the first patient was enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA.
Learn How the Ongoing Clinical & Commercial Activities will Affect the Metastatic Colorectal Cancer Therapeutic Segment @
Metastatic Colorectal Cancer Therapeutics Landscape
The goal of treatment for metastatic colorectal cancer is usually to prolong life and relieve or prevent symptoms. Treating colon cancer that has spread to other organs often requires a combination of different treatments. These may include surgery, chemotherapy, image-guided therapies, such as MRI and CT, radiation therapy, targeted therapies, and immunotherapy.
To improve the treatment scenario, there are approx. 140+ key companies developing therapies for Metastatic Colorectal Cancer. G1 Therapeutics is leading the therapeutics market with its Metastatic Colorectal cancer drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Metastatic Colorectal Cancer Therapeutics Market Include:
G1 Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shanghai Henlius Biotech, Amarin Corporation, Mologen, Sumitomo Dainippon Pharma Oncology, Celltrion, Merck Sharp & Dohme, Jiangsu Hengrui Medicine, Suzhou Zelgen Biopharmaceuticals, Mabpharm Limitied, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical, Isofol Medical, Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine, AB Science, Gritstone Bio, Inc, Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Sunshine Guojian Pharmaceutical, Pfizer, Merck KGaA, Jiangsu HengRui Medicine Co., Ltd., ALX Oncology, Immunovative Therapies, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Precision Biologics, Sanofi, GC Pharma, VAXIMM, AstraZeneca, Yooyoung Pharmaceutical, Med Pacto Inc., Exelixis, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme, Bavarian Nordic, Maxinovel Pharmaceuticals, Shanghai Henlius Biotech, Novartis, Zucero Therapeutics, Innovent Biologics, Scandion Oncology, Merck Sharp & Dohme Corp., AbbVie, Beijing Biostar Technologies, Seagen Inc, Merck KGaA, Teclison Ltd, Symphogen A/S, Sichuan Baili Pharmaceutical; SystImmune, Karyopharm Therapeutics, and several others.
Metastatic Colorectal Cancer Drugs Covered in the Report Include:
Trilaciclib: G1 Therapeutics
Famitinib: Jiangsu Hengrui Medicine
CMAB009: Mabpharm Limited
Trastuzumab Deruxtecan: Daiichi Sankyo
SCO-101: Scandion Oncology
BEY 1107: BeyondBio
Etrumadenant: Arcus Biosciences
CYAD 101: Celyad Oncology
Sym004: Symphogen A/S
Onvansertib: Cardiff Oncology
PolyPEPI 1018: Treos Bio
MRTX849: Mirati Therapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Metastatic Colorectal Cancer Current Treatment Patterns
4. Metastatic Colorectal Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Colorectal Cancer Late Stage Products (Phase-III)
7. Metastatic Colorectal Cancer Mid-Stage Products (Phase-II)
8. Metastatic Colorectal Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Colorectal Cancer Discontinued Products
13. Metastatic Colorectal Cancer Product Profiles
14. Key Companies in the Metastatic Colorectal Cancer Market
15. Key Products in the Metastatic Colorectal Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. Metastatic Colorectal Cancer Unmet Needs
18. Metastatic Colorectal Cancer Future Perspectives
19. Metastatic Colorectal Cancer Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Other Trending Healthcare Reports By DelveInsight
“Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast 2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Metastatic Colorectal Cancer market size, shares, and trends analysis in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States